Major trial aims to stop second strokes with Anti-Inflammatory drug

NCT ID NCT05476991

Summary

This large Phase 3 trial is testing whether adding two common medications to standard care can prevent future strokes, heart attacks, and other major vascular problems in high-risk patients who have recently had a stroke. It will compare a low-dose anti-inflammatory drug (colchicine) and a blood thinner (ticagrelor) against standard treatments over 3-5 years. The goal is to see if these drugs can better control the underlying inflammation and clotting that cause repeat events.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • URC Lariboisière-Fernand Widal-Saint Louis

    RECRUITING

    Paris, Paris, 75010, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.